This guideline is intended to provide requirements to applicants wishing to submit
applications for registration of medicines in Botswana.
Medical Journal of Zambia, Volume 36 Number 4 (2009)
10 years after the UN general assembly special session on drugs
Paper commissioned for the EFA Global Monitoring Report 2010, Reaching the marginalized
The purpose of this document is to provide a comprehensive overview of existing institutional arrangement for disaster management in Myanmar at all levels with an aim to make information available to all stakeholders involved in disaster risk management in Myanmar.
The Water, Sanitation, and Hygiene Improvement Training Package is intended to support the training of local outreach workers and their subsequent work in communities to promote improved water, sanitation and hygiene (WASH) practices to reduce diarrhea
The Capacity Project worked to strengthen HRIS in several low-resource countries to assist decision-makers and human resources managers in identifying and responding to critical gaps in HRH. The findings and recommendations in this report cover the Capacity Project’s implementation of HRIS in Swaz...iland, Rwanda and Uganda.
more
A Decade of Change for Newborn Survival: Bangladesh
This Indicator-Based Pharmacovigilance Assessment Tool (IPAT) was developed as a comprehensive performance metric for pharmacovigilance and medicine safety systems.
PQM conducted an assessment of the medicine quality assurance and quality control systems in Rwanda during November 9-13, 2009. Medicine quality assurance remains to be developed in Rwanda: the country has neither a medicine regulatory authority (MRA) nor a national medicine quality control laborato...ry – the two key institutions to ensure the quality, safety, and efficacy of medicines. The MOH Pharmacy Taskforce (PTF) is to be commended however for successfully controlling the pharmaceutical market to the extent that there is no informal medicines market in Rwanda. Based on its findings, the assessment team expects Rwanda to be able to make great strides in evidence-based medicines quality assurance in the short to medium term, provided it receives adequate technical assistance and financial support.
more